




Instance: composition-en-7957aafe253d586bcd1a37e5702661ef
InstanceOf: CompositionUvEpi
Title: "Composition for hetlioz Package Leaflet"
Description:  "Composition for hetlioz Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb81dfb5a762a9951211e527b6f56d795)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - hetlioz"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What HETLIOZ is and what it is used for  </li>
<li>What you need to know before you take HETLIOZ  </li>
<li>How to take HETLIOZ  </li>
<li>Possible side effects  </li>
<li>How to store HETLIOZ </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What hetlioz is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What hetlioz is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HETLIOZ contains the active substance tasimelteon.  This type of medicine is called a  melatonin agonist<br />
that acts as a regulator of daily body rhythms. </p>
<p>It is used to treat Non-24-Hour Sleep-Wake Disorder (Non-24) in adults who are totally blind. </p>
<p>How HETLIOZ works 
In sighted people, the change in light levels between day and night helps to synchronise internal body 
rhythms, including feeling sleepy at night and being active during the day. The body controls these rhythms 
through many pathways including increases and decreases in the production of the hormone melatonin.  </p>
<p>Patients with Non-24 who are totally blind cannot see light, so their body rhythms shift out of alignment with 
the 24-hour world, resulting in periods of feeling sleepy during the day and the inability to sleep at night. The 
active substance in HETLIOZ, tasimelteon, is able to act as a time-keeper for the body rhythms and resets 
them each day.  It aligns body rhythms with the usual 24-hour day and night cycle and so improve sleep 
patterns. Because of individual differences in each person s body rhythms, it could take weeks or up to 3 
months for an improvement in symptoms to be noticed.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take hetlioz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take hetlioz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take HETLIOZ if 
You are allergic to tasimelteon or any of the other ingredients of this medicine (listed in section 6). </p>
<p>Warnings and precautions 
After taking HETLIOZ, you should get ready to go to bed and only carry out activities that you would 
normally do before going to bed. </p>
<p>Children and adolescents 
Do not give HETLIOZ to children under the age of 18 years.  This is because HETLIOZ has not been tested 
in people under 18 years of age and the effects are unknown.  </p>
<p>Other medicines and HETLIOZ 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.  This 
includes:</p>
<ul>
<li>medicines known to reduce the activity of an enzyme called  CYP1A2 .  An example is 
fluvoxamine, which is used to treat depression and obsessive compulsive disorder (OCD).   </li>
<li>medicines known to reduce the activity of an enzyme called  CYP3A4 .  An example is 
ketoconazole, which is used to treat fungal infections. </li>
<li>medicines known to increase the activity of an enzyme called  CYP3A4 .  An example is rifampicin, 
which is used to treat tuberculosis (TB). </li>
<li>medicines known to reduce the activity of an enzyme called  CYP2C19 .  An example is 
omeprazole, which is used to treat hearburn and gastroesophageal reflux disease (GERD). </li>
<li>medicines called  beta blockers  used to treat high blood pressure and other heart problems.  Some 
examples include atenolol, metoprolol, and propanolol. </li>
</ul>
<p>If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking 
HETLIOZ. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your 
doctor or pharmacist for advice before taking this medicine.  As a precautionary measure, it is preferable to 
avoid the use of tasimelteon during pregnancy.  If you become pregnant while taking HETLIOZ, consult 
your doctor immediately as it is recommended not to take HETLIOZ while you are pregnant or breast 
feeding. </p>
<p>HETLIOZ contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before 
taking this medicine. </p>
<p>HETLIOZ contains Orange Yellow S (E110) 
Tell your doctor if you have an allergy to Orange Yellow S (E110).  HETLIOZ contains Orange Yellow S 
(E110) which may cause allergic reactions. </p>
<p>HETLIOZ contains sodium<br />
This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take hetlioz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take hetlioz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you.  Check with your doctor or 
pharmacist if you are not sure. </p>
<p>How much to take 
The recommended dose is one capsule every night, taken one hour before you go to bed. Try to take the 
medicine at the same time every night.  Because of individual differences in each person s body rhythms, it 
could take weeks or months for you to notice an improvement in your symptoms.  Therefore, your doctor 
may ask you to take HETLIOZ for up to 3 months before checking if it is working for you. </p>
<p>Taking HETLIOZ 
- Take the medicine by mouth. 
- Swallow the capsule whole.<br />
- It is best to take HETLIOZ on an empty stomach as food can reduce the amount of the medicine that 
is absorbed into your body.  If you eat a high-fat meal close to the time you would normally take the 
medicine, it is best to wait 2 hours before taking HETLIOZ.<br />
- To open the bottle, push the cap down and turn counter-clockwise. </p>
<p>If you take more HETLIOZ than you should 
If you accidentally take more HETLIOZ than your doctor recommended, contact your doctor at once or 
contact the nearest hospital for advice. Keep the bottle with you so that you can easily describe what you 
have taken. </p>
<p>If you forget to take HETLIOZ 
- Skip the missed dose.  Take your next dose at the usual time the next day. Do not take a double dose. </p>
<p>If you stop taking HETLIOZ 
Do not stop taking HETLIOZ without talking to your doctor. 
- If HETLIOZ is not taken every night, the body rhythms will lose alignment with the usual 24-hour 
day and night cycle again.  This means that  symptoms will come back. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following 
side effects may happen with this medicine. </p>
<p>Very common: may affect more than 1 in 10 people 
- headache </p>
<p>Common: may affect up to 1 in 10 people 
- change in sleeping pattern 
- difficulty in sleeping 
- dizziness 
- dry mouth 
- tiredness 
- indigestion 
- feeling sick in the stomach 
- blood tests which show changes in the way the liver is working (alanine aminotransferase) 
- unusual dreams 
- sleepiness </p>
<p>Uncommon: may affect up to 1 in 100 people 
- abnormal or change in taste 
- blood tests which show changes in the way the liver is working (aspartate aminotransferase and 
gamma-glutamyl transferase) 
- increase in daytime urination 
- nightmares 
- ringing in the ears 
- feeling foggy in the head </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed 
in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix 
V. By reporting side effects, you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store hetlioz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store hetlioz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Keep this medicine out of the sight and reach of children. </li>
<li>Do not use this medicine after the expiry date which is stated on the bottle and the carton after EXP. 
The expiry date refers to the last day of that month. </li>
<li>This medicine does not require any special temperature storage conditions.  </li>
<li>Store in the original container and keep the bottle tightly closed in order to protect from moisture and 
light. </li>
<li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What HETLIOZ contains<br />
- The active substance is tasimelteon.  Each hard capsule contains 20 mg of tasimelteon. 
- The other ingredients are lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, silica, 
colloidal anhydrous, and magnesium stearate. <br />
- The hard capsule shell consists of gelatin, titanium dioxide , Brilliant Blue FCF , Erythrosine , and 
Orange Yellow S (E 110).<br />
- The white printing ink contains shellac, propylene glycol, sodium hydroxide, povidone  and titanium 
dioxide. </p>
<p>What HETLIOZ looks like and contents of the pack 
HETLIOZ hard capsules are opaque dark blue printed with  VANDA 20 mg  in white.  Each bottle has a 
child-resistant cap and contains 30 hard capsules.  </p>
<p>Marketing Authorisation Holder 
Vanda Pharmaceuticals Netherlands B.V. 
Basisweg 1043 AP Amsterdam 
The Netherlands </p>
<p>Manufacturer 
AcertiPharma B.V. 
Boschstraat 4811 GC Breda 
The Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Vanda Pharmaceuticals Netherlands B.V. 
T l/Tel: +49 (0)30 800 98Lietuva 
Vanda Pharmaceuticals Netherlands B.V. 
Tel. +49 (0)30 800 98<br />
Vanda Pharmaceuticals Netherlands B.V. 
Te : +49 (0)30 800 98Luxembourg/Luxemburg 
Vanda Pharmaceuticals Netherlands B.V. 
T l/Tel: +49 (0)30 800 98 esk  republika 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Magyarorsz g 
Vanda Pharmaceuticals Netherlands B.V. 
Tel.: +49 (0)30 800 98Danmark 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf: +49 (0)30 800 98Malta 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Deutschland 
Nederland 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Eesti 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Norge 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf: +49 (0)30 800 98<br />
Vanda Pharmaceuticals Netherlands B.V. 
T : +49 (0)30 800 98 sterreich 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Espa a 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Polska 
Vanda Pharmaceuticals Netherlands B.V. 
Tel.: +49 (0)30 800 98France 
Vanda Pharmaceuticals Netherlands B.V. 
T l: +49 (0)30 800 98Portugal 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Hrvatska 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Rom nia 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Ireland 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Slovenija 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98 sland 
Vanda Pharmaceuticals Netherlands B.V. 
S mi: +49 (0)30 800 98Slovensk  republika 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Italia 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Suomi/Finland 
Vanda Pharmaceuticals Netherlands B.V. 
Puh/Tel: +49 (0)30 800 98<br />
Vanda Pharmaceuticals Netherlands B.V. 
T : +49 (0)30 800 98Sverige 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98Latvija 
Vanda Pharmaceuticals Netherlands B.V. 
+49 (0)30 800 98United Kingdom (Northern Ireland) 
Vanda Pharmaceuticals Netherlands B.V. 
Tel: +49 (0)30 800 98This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-7957aafe253d586bcd1a37e5702661ef
InstanceOf: CompositionUvEpi
Title: "Composition for hetlioz Package Leaflet"
Description:  "Composition for hetlioz Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb81dfb5a762a9951211e527b6f56d795)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - hetlioz"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at tage HETLIOZ  </li>
<li>Sådan skal du tage HETLIOZ   </li>
<li>Bivirkninger  </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What hetlioz is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What hetlioz is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HETLIOZ indeholder det aktive stof tasimelteon. Denne type lægemiddel kaldes en “melatoninagonist" og 
virker som en regulator af kroppens døgnrytme. </p>
<p>Det anvendes til behandling af søvnforstyrrelsen Non-24-Hour Sleep-Wake Disorder (Non-24) hos voksne, 
der er totalt blinde. </p>
<p>Sådan virker HETLIOZ 
Hos seende personer bevirker ændringen fra dagslys til nat, at kroppens indre døgnrytme bliver 
synkroniseret, så man er søvnig om natten og aktiv om dagen. Kroppen regulerer disse rytmer ad en lang 
række veje, herunder gennem tiltagende og aftagende produktion af hormonet melatonin.  </p>
<p>Fuldstændig blinde patienter med Non-24 kan ikke se lys. Derfor kommer deres kropsrytme ud af trit med 
24-timers verdenen, så de i perioder er søvnige om dagen og søvnløse om natten. Det aktive stof i HETLIOZ, 
tasimelteon, kan virke som en tidstager for kroppens rytmer og regulere dem hvert døgn. Det retter kroppens 
rytmer ind efter den normale 24-timers dag-og-nat cyklus og giver derved et bedre søvnmønster. Der er 
forskelle i kropsrytme hos forskellige personer, og det kan således tage flere uger eller op til 3 måneder, før 
der mærkes bedring i symptomerne.   </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take hetlioz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take hetlioz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke HETLIOZ: 
hvis du er allergisk over for tasimelteon eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i 
afsnit 6). </p>
<p>Advarsler og forsigtighedsregler 
Når du har taget HETLIOZ, skal du gøre dig klar til at gå i seng og kun gøre, hvad du plejer at gøre, før du 
går i seng. </p>
<p>Børn og unge 
Giv ikke HETLIOZ til børn under 18 år.  Dette skyldes, at HETLIOZ ikke er testet hos personer under 18 år, 
og virkningerne kendes ikke.  </p>
<p>Brug af anden medicin sammen med HETLIOZ 
Fortæl det altid til lægen eller på apoteket, hvis du bruger anden medicin, har gjort det for nylig eller 
påtænker at gøre det. Dette gælder således:</p>
<ul>
<li>lægemidler, der nedsætter aktiviteten af enzymet CYP1A2. Et eksempel er fluvoxamin, der anvendes 
mod depression og mod tvangstanker og tvangshandlinger (obsessiv-kompulsiv lidelse (OCD)),   </li>
<li>lægemidler, der nedsætter aktiviteten af enzymet CYP3A4. Et eksempel er ketoconazol, der 
anvendes til behandling af svampeinfektioner, </li>
<li>lægemidler, der øger aktiviteten af enzymet CYP3A4. Et eksempel er rifampicin, der anvendes til 
behandling af tuberkulose, </li>
<li>lægemidler, der nedsætter aktiviteten af enzymet CYP2C19. Et eksempel er omeprazol, der anvendes 
til behandling af halsbrand og tilbageløb af maveindholdet (gastroøsofagealt reflukssygdom), </li>
<li>lægemidler af typen betablokkere, der anvendes mod højt blodtryk og andre hjerteproblemer. Som 
eksempel kan nævnes atenolol, metoprolol og propranolol. </li>
</ul>
<p>Hvis ét eller flere af ovenstående punkter passer på dig (eller du ikke er sikker), skal du tale med lægen eller 
apotekspersonalet, inden du tager HETLIOZ. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har en formodning om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge lægen eller apotekspersonalet til råds, før du bruger dette lægemiddel.  Som en forsigtighedsregel 
foretrækkes det at undgå brug af tasimelteon under graviditet. Hvis du bliver gravid, mens du tager 
HETLIOZ, skal du straks kontakte lægen, da det anbefales ikke at bruge HETLIOZ, når man er gravid eller 
ammer. </p>
<p>HETLIOZ indeholder lactose<br />
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. </p>
<p>HETLIOZ indeholder Orange Yellow S (E110) 
Sig det til lægen, hvis du er allergisk over for Orange Yellow S (E110).<br />
 HETLIOZ indeholder Orange Yellow S (E110), som kan forårsage allergiske reaktioner. </p>
<p>HETLIOZ indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. kapsel, dvs. det er i det væsentlige 
natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take hetlioz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take hetlioz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg lægen 
eller på apoteket. </p>
<p>Hvor meget skal du tage? 
Den anbefalede dosis er én kapsel hver aften, som tages en time før sengetid. Prøv at tage lægemidlet på 
samme klokkeslæt hver aften. På grund af individuelle forskelle i kropsrytme kan det tage uger eller op til tre 
måneder, før du mærker bedring i dine symptomer. Derfor vil lægen måske bede dig tage HETLIOZ i op til 
tre måneder og vil først derefter kontrollere, om det virker på dig. </p>
<p>Sådan skal du tage HETLIOZ 
- Tag lægemidlet gennem munden. 
- Synk kapslen hel.<br />
- Tag helst HETLIOZ på tom mave, da føde kan nedsætte den mængde af lægemidlet, der optages i 
kroppen. Hvis du spiser et fedtrigt måltid omkring det tidspunkt, hvor du plejer at tage lægemidlet, er 
det bedst at vente to timer med at tage HETLIOZ.<br />
- For at åbne flasken skal du trykke låget ned og skrue modsat urretningen. </p>
<p>Hvis du har taget for meget HETLIOZ 
Hvis du er kommet til at tage mere HETLIOZ end lægen har anbefalet, skal du straks kontakte lægen eller 
nærmeste akutmodtagelse for at få rådgivning. Tag flasken med dig, så du let kan beskrive, hvad du har 
taget. </p>
<p>Hvis du har glemt at tage HETLIOZ 
- Overspring den glemte dosis. Tag næste dosis til sædvanlig tid næste dag. Du skal ikke tage en 
dobbelt dosis. </p>
<p>Hvis du holder op med at tage HETLIOZ 
Du må ikke holde op med at tage HETLIOZ uden at have talt med lægen.<br />
- Hvis du ikke tager HETLIOZ hver aften, vil din krop igen komme ud af trit med den normale 24-
timers døgnrytme. Det vil få symptomerne til at komme igen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide om brugen af lægemidlet. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. Følgende 
bivirkninger kan forekomme med dette lægemiddel: </p>
<p>Meget almindelig: forekommer hos mere end 1 ud af 10 personer 
- hovedpine </p>
<p>Almindelig: forekommer hos op til 1 ud af 10 personer) 
- ændret søvnmønster 
- søvnbesvær 
- svimmelhed 
- mundtørhed 
- træthed 
- fordøjelsesbesvær 
- kvalme 
- ændring i blodprøver, der viser hvordan leveren fungerer (alaninaminotransferase) 
- usædvanlige drømme 
- søvnighed </p>
<p>Ikke almindelig: forekommer hos op til 1 ud af 100 personer) 
- unormale eller ændrede smagsindtryk 
- ændring i blodprøver, der viser hvordan leveren fungerer (aspartataminotransferase og 
gammaglutamyltransferase)  </p>
<ul>
<li>hyppigere vandladning i dagtimerne </li>
<li>mareridt </li>
<li>ringen for ørerne </li>
<li>omtågethed </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apoteket. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem anført i appendiks V. Ved at 
indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om dette lægemiddels 
sikkerhed. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store hetlioz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store hetlioz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Opbevar lægemidlet utilgængeligt for børn. </li>
<li>Brug ikke dette lægemiddel efter den udløbsdato, der står på etiketten og på kartonen. Udløbsdatoen 
er den sidste dag i den nævnte måned. </li>
<li>Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel.Opbevares i den 
originale emballage og flasken skal holdes tæt tillukket for at beskytte mod fugt og lys. </li>
<li>Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. Spørg 
på apoteket, hvordan du skal bortskaffe medicinrester. Derved skåner du miljøet. </li>
</ul>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>HETLIOZ indeholder: <br />
− 
Aktivt stof: tasimelteon. Hver hård kapsel indeholder 20 mg tasimelteon. 
− 
Øvrige indholdsstoffer: vandfri laktose, mikrokrystallinsk cellulose, croscarmellosenatrium, silica, 
vandfri kolloid  og magnesiumstearat.<br />
− 
Kapslens skal består af gelatine, titaniumdioxid, Brilliant Blue FCF, erytrocin og Orange Yellow S 
(E110). <br />
− 
Den hvide trykfarve indeholder shellac, propylenglycol, natriumhydroxid, povidon og titaniumdioxid. </p>
<p>Udseende og pakningsstørrelser 
HETLIOZ, hårde kapsler, er uigennemsigtige mørkeblå kapsler påtrykt “VANDA 20 mg" med hvid farve. 
Hver flaske har børnesikret låg og indeholder 30 hårde kapsler.  </p>
<p>Indehaver af markedsføringstilladelsen 
Vanda Pharmaceuticals Netherlands B.V. 
Basisweg 10<br />
1043 AP Amsterdam 
Holland </p>
<p>Fremstiller </p>
<p>AcertiPharma B.V. 
Boschstraat 51<br />
4811 GC Breda 
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale repræsentant 
for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Vanda Pharmaceuticals Netherlands B.V. 
Tél/Tel: +49 0 30 800 98Lietuva 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: (+490) 30 800 98 
България 
Vanda Pharmaceuticals Netherlands B.V. 
Teл: +49 0 30 800 98 
Luxembourg/Luxemburg 
Vanda Pharmaceuticals Netherlands B.V. 
Tél/Tel: +49 0 30 800 98Česká republika 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98Magyarország 
Vanda Pharmaceuticals Netherlands B.V. 
Tél./Tel. +49 0 30 800 98Danmark 
Malta 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf: +49 0 30 800 98Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Deutschland 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Nederland 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98Eesti 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98Norge 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf: +49 0 30 800 98 
Ελλάδα 
Vanda Pharmaceuticals Netherlands B.V. 
Tηλ.: +49 0 30 800 98Österreich 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
España 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98Polska 
Vanda Pharmaceuticals Netherlands B.V. 
Tél./Tel. +49 0 30 800 98 
Frankrig 
Vanda Pharmaceuticals Netherlands B.V. 
Tél: +49 0 30 800 98Portugal 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Hrvatska 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
România 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Irleand 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Slovenija 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Ísland 
Vanda Pharmaceuticals Netherlands B.V. 
Sími: +49 0 30 800 98Slovenská republika 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Italia 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98Suomi/Finland 
Vanda Pharmaceuticals Netherlands B.V. 
Puh/Tel: +49 0 30 800 98 
Κύπρος 
Vanda Pharmaceuticals Netherlands B.V. 
Tηλ: +49 0 30 800 98Sverige 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 
Latvija 
Vanda Pharmaceuticals Netherlands B.V. 
+49 0 30 800 98Det Forenede Kongerige (Nordirland) 
Vanda Pharmaceuticals Netherlands B.V. 
Tlf.: +49 0 30 800 98 </p>
<p>Denne indlægsseddel blev senest revideret   </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere information om dette lægemiddel på Det europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-7957aafe253d586bcd1a37e5702661ef
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for hetlioz Package Leaflet for language en"
Description: "ePI document Bundle for hetlioz Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-7957aafe253d586bcd1a37e5702661ef"
* entry[0].resource = composition-en-7957aafe253d586bcd1a37e5702661ef

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7957aafe253d586bcd1a37e5702661ef"
* entry[=].resource = mp7957aafe253d586bcd1a37e5702661ef
                            
                    
Instance: bundlepackageleaflet-da-7957aafe253d586bcd1a37e5702661ef
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for hetlioz Package Leaflet for language da"
Description: "ePI document Bundle for hetlioz Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-7957aafe253d586bcd1a37e5702661ef"
* entry[0].resource = composition-da-7957aafe253d586bcd1a37e5702661ef

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7957aafe253d586bcd1a37e5702661ef"
* entry[=].resource = mp7957aafe253d586bcd1a37e5702661ef
                            
                    



Instance: mp7957aafe253d586bcd1a37e5702661ef
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product HETLIOZ 20 mg hard capsules"
Description: "HETLIOZ 20 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/15/1008/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "HETLIOZ 20 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 7957aafe253d586bcd1a37e5702661efListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "hetlioz"

* status = #current
* mode = #working

* title = "List of all ePIs associated with hetlioz"

* subject = Reference(mpb81dfb5a762a9951211e527b6f56d795)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#hetlioz "hetlioz"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-7957aafe253d586bcd1a37e5702661ef) // hetlioz en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-7957aafe253d586bcd1a37e5702661ef) // hetlioz da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-7957aafe253d586bcd1a37e5702661ef
InstanceOf: List

* insert 7957aafe253d586bcd1a37e5702661efListRuleset
    